{"id":"W2772341954","doi":"10.1093/annonc/mdx711.078","title":"KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Cetuximab; Response Evaluation Criteria in Solid Tumors; Tolerability; Internal medicine; Oncology; Clinical endpoint; Regimen; Phases of clinical research; Head and neck squamous-cell carcinoma; Clinical trial; Head and neck cancer; Cancer; Adverse effect; Immunotherapy; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000239307,0.0002340437,0.001197653,0.0001959365,0.00007860755,0.000006362925,0.0002707673,0.0001038726,0.0001113669],"category_scores_gemma":[0.0005473799,0.0001686524,0.0001224248,0.0001016191,0.0003904084,0.00007303783,0.0001260153,0.0002211713,0.000008620234],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000116418,"about_ca_system_score_gemma":0.0005882878,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003415164,"about_ca_topic_score_gemma":0.0004595489,"domain_scores_codex":[0.998063,0.0001366566,0.0006963279,0.0003444924,0.0003654523,0.0003940852],"domain_scores_gemma":[0.9976315,0.000321666,0.0008962561,0.0006769654,0.0003511218,0.0001224927],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7505192,0.01652865,0.06887861,0.0008382222,0.0002644255,0.00187713,0.001844126,0.000007207584,0.000184356,0.00003232287,0.005550651,0.1534751],"study_design_scores_gemma":[0.5615007,0.2836941,0.129058,0.0002156031,0.0006127406,0.0001804585,0.0003426592,0.00005448263,0.01082747,0.000109313,0.0129746,0.0004299388],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888622,0.0003407667,0.000005070708,0.0008854982,0.0004326485,0.00117508,0.00007003841,0.00000757656,0.008221094],"genre_scores_gemma":[0.9988787,0.000135867,0.0003598685,0.0001732125,0.0001053077,0.00006753371,0.00001617139,0.00002787364,0.0002355198],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2671654,"threshold_uncertainty_score":0.6877447,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09981705411407019,"score_gpt":0.4088673511182487,"score_spread":0.3090502970041785,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}